Tech Company Financing Transactions
Endocyte Funding Round
Endocyte, operating out of West Lafayette, scored $15 million from Blue Chip Venture Company, Burrill & Company and CID Capital.
Transaction Overview
Company Name
Announced On
3/23/2007
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series C
Investors
Proceeds Purpose
The funds will support the development of Endocyte's folate-targeted cancer therapies including three phase 2 clinical studies and one phase 1 study. The studies will target cancers including renal cell carcinoma, ovarian cancer and non-small cell lung cancer. Endocyte also will continue its development efforts related to autoimmune therapies and extend its pipeline with next-generation oncology drugs.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3000 Kent Ave.
West Lafayette, IN 47906
USA
West Lafayette, IN 47906
USA
Phone
Website
Email Address
Overview
Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Sherman
Chief Financial Officer
Michael Andriole
Chief Medical Officer
Alison Armour
Chief Scientific Officer
Philip Low
Vice President
Iontcho Vlahov
VP - Bus. Development
Matthew Call
VP - Finance
Beth Taylor
VP - Human Resources
Katherine Parker
VP - R & D
Christopher Leamon
Browse more venture capital transactions:
Prev: 3/22/2007: Skylight Healthcare Systems venture capital transaction
Next: 3/23/2007: Amira Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs